Steve Sabus - Syndax Pharmaceuticals Chief Officer
| SNDX Stock | USD 14.10 0.98 7.47% |
Executive
Steve Sabus is Chief Officer of Syndax Pharmaceuticals
| Age | 57 |
| Address | 730 Third Avenue, New York, NY, United States, 10017 |
| Phone | 781 419 1400 |
| Web | https://www.syndax.com |
Syndax Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3174) % which means that it has lost $0.3174 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7569) %, meaning that it created substantial loss on money invested by shareholders. Syndax Pharmaceuticals' management efficiency ratios could be used to measure how well Syndax Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.46 in 2025. Return On Capital Employed is likely to drop to -0.57 in 2025. At this time, Syndax Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 127.8 M in 2025, whereas Non Currrent Assets Other are likely to drop slightly above 206.2 K in 2025.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| Mary CPA | Cullinan Oncology LLC | 61 | |
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Jose CPA | Mineralys Therapeutics, Common | 35 | |
| Daniel Wilson | Dyne Therapeutics | 53 | |
| HansPeter Gerber | Sutro Biopharma | 62 | |
| Robert McKean | Mineralys Therapeutics, Common | N/A | |
| Pamela Esposito | Replimune Group | 50 | |
| Marc MD | Edgewise Therapeutics | 68 | |
| Lily Cheung | Pliant Therapeutics | 52 | |
| Melissa Manno | Viridian Therapeutics | N/A | |
| Christopher Keenan | Pliant Therapeutics | N/A | |
| Christopher Yea | Kalvista Pharmaceuticals | 61 | |
| Sanjeev Khindri | Aerovate Therapeutics | N/A | |
| Gayle Gironda | Inozyme Pharma | N/A | |
| Trevor Hallam | Sutro Biopharma | 65 | |
| Shan Wu | Viridian Therapeutics | N/A | |
| BSc MD | Aerovate Therapeutics | N/A | |
| Brett Pletcher | Cytokinetics | 56 | |
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Jennifer Johansson | Larimar Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.32 |
Syndax Pharmaceuticals Leadership Team
Elected by the shareholders, the Syndax Pharmaceuticals' board of directors comprises two types of representatives: Syndax Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Syndax. The board's role is to monitor Syndax Pharmaceuticals' management team and ensure that shareholders' interests are well served. Syndax Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Syndax Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Briggs MD, Head Pres | ||
| Steven Closter, Chief Officer | ||
| Michael MBA, CEO Director | ||
| Steve Sabus, Chief Officer | ||
| Joseph MD, Member Officer | ||
| Ronald Evans, Advisor CoFounder | ||
| Sharon Klahre, Vice Communications | ||
| Peter BSc, CoFounder Officer | ||
| Anjali Ganguli, Chief Officer | ||
| Alexander Nolte, VP Officer | ||
| Neil MD, President Development | ||
| Luke JD, General VP | ||
| Kevin McManus, Chief Officer | ||
| Michael Downes, CoFounder | ||
| Luke Albrecht, General VP | ||
| Richard Heyman, CoFounder | ||
| Catherine MD, Chief Officer | ||
| Keith CPA, Chief Officer |
Syndax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Syndax Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.76 | ||||
| Return On Asset | -0.32 | ||||
| Operating Margin | (12.55) % | ||||
| Current Valuation | 891.47 M | ||||
| Shares Outstanding | 86.02 M | ||||
| Shares Owned By Insiders | 1.29 % | ||||
| Shares Owned By Institutions | 98.71 % | ||||
| Number Of Shares Shorted | 21.55 M | ||||
| Price To Earning | 126.11 X | ||||
| Price To Book | 3.92 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Syndax Stock Analysis
When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.